Mangoceuticals, which provides an erectile dysfunction product via telehealth, postponed its IPO on Wednesday. It had most recently filed to raise $5 million by offering 1.3 million shares at $4, and was set to price later this week.
The Dallas, TX-based company was founded in 2021 and had planned to list on the Nasdaq under the symbol MGRX. Boustead Securities was set to be the sole bookrunner on the deal.
